Glazer Capital LLC bought a new stake in shares of Simulations Plus, Inc. (NASDAQ:SLP - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 201,564 shares of the technology company's stock, valued at approximately $3,691,000. Glazer Capital LLC owned approximately 1.00% of Simulations Plus at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in Simulations Plus in the 2nd quarter valued at $25,000. Quarry LP acquired a new position in shares of Simulations Plus during the third quarter worth about $28,000. GAMMA Investing LLC boosted its position in shares of Simulations Plus by 26.0% in the second quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company's stock worth $52,000 after buying an additional 585 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Simulations Plus by 59.3% in the first quarter. PNC Financial Services Group Inc. now owns 4,485 shares of the technology company's stock worth $53,000 after buying an additional 1,669 shares during the period. Finally, Fifth Third Bancorp purchased a new stake in shares of Simulations Plus in the first quarter worth about $54,000. 78.08% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other Simulations Plus news, Director Walter S. Woltosz sold 4,177 shares of the firm's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $18.44, for a total transaction of $77,023.88. Following the completion of the sale, the director owned 3,202,131 shares in the company, valued at $59,047,295.64. This trade represents a 0.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.10% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Several brokerages recently commented on SLP. Wall Street Zen downgraded Simulations Plus from a "buy" rating to a "hold" rating in a report on Saturday, June 13th. Weiss Ratings upgraded Simulations Plus from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, July 10th. William Blair downgraded shares of Simulations Plus from an "outperform" rating to a "market perform" rating in a research report on Wednesday, June 17th. Finally, Craig Hallum lowered shares of Simulations Plus from a "buy" rating to a "hold" rating and set a $18.50 price objective on the stock. in a research note on Thursday, June 18th. Seven analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Simulations Plus currently has a consensus rating of "Reduce" and a consensus price target of $17.25.
Check Out Our Latest Report on Simulations Plus
Simulations Plus Price Performance
NASDAQ:SLP opened at $18.42 on Friday. The firm has a 50-day moving average of $18.30 and a two-hundred day moving average of $15.39. The stock has a market cap of $372.54 million, a P/E ratio of 46.05 and a beta of 1.32. Simulations Plus, Inc. has a 1-year low of $11.09 and a 1-year high of $21.01.
Simulations Plus (NASDAQ:SLP - Get Free Report) last announced its earnings results on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.07. Simulations Plus had a return on equity of 13.50% and a net margin of 9.88%.The business had revenue of $21.89 million for the quarter, compared to analyst estimates of $20.90 million.
Simulations Plus Company Profile
(
Free Report)
Simulations Plus, Inc NASDAQ: SLP specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company's flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Simulations Plus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Simulations Plus wasn't on the list.
While Simulations Plus currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.